USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/11878
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTelevca, Irina-
dc.date.accessioned2020-10-01T19:18:17Z-
dc.date.available2020-10-01T19:18:17Z-
dc.date.issued2016-
dc.identifier.citationTELEVCA, Irina. The immune process in the pathogenesis of tumors. In: MedEspera: the 6th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2016, p. 292.en_US
dc.identifier.isbn978-9975-3028-3-8.-
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/11878-
dc.descriptionDepartment of Physiopathology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova, The 6th International Medical Congress for Students and Young Doctorsen_US
dc.description.abstractIntroduction: The immune process in the pathogenesis of the tumors represents an actual subject for the prevention and the treatment of the cancer, which frequency is decreasing while studying the newest theories of the etiopathology of cancer, a disease that is the common cause of death. The objective of this study is to review the newest methods, that explain the role of the immune processes in the pathology and the treatment of tumors. Material and methods: Informational support for the development of this publication has served a full amount of current national and international journals, which are concerned with tumors, found through the „PubMed” „Google” and „CrossRefMedlineWeb of Science”. After entering the filters: the immune process in the pathogenesis of tumors were selected 20 sources. Results: After studying the interaction between the immune system and the tumors, different immunotherapies were identified: the new therapeutic monoclonal antibodies, that were approved by the Food and Drug Administration, as a standard treatment in some forms of cancer, Associated with trastuzumab for mamar cancer and rituximab for the B cells lymphoma, and the vaccines, which are starting to be used in clinical practice, either alone or in various combinations. Conclusions: Much has been learned about the potential of the immune system to control cancer and the various ways that immunotherapy can boost the potential of the immune system for the benefit of the patient. This knowledge has stimulated the invention of many new therapeutic antibodies, cellbased treatments, and vaccines, which are starting to be used in clinical practice, either alone or in various combinations. These new therapies are expected to result in improved cancer treatment and, eventually, the prevention of cancer.en_US
dc.language.isoenen_US
dc.publisherMedEsperaen_US
dc.subjectThe hallmarks of canceren_US
dc.subjectthe immunology of canceren_US
dc.subjectimunogenicityen_US
dc.subjectimmunosuppressionen_US
dc.subjectimmunotherapiesen_US
dc.titleThe immune process in the pathogenesis of tumorsen_US
dc.typeArticleen_US
Appears in Collections:MedEspera 2016

Files in This Item:
File Description SizeFormat 
The_immune_process_in_the_pathogenesis_of_tumors.pdf261.88 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback